DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers

Information source: Crucell Holland BV
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Influenza

Intervention: Inflexal V influenza vaccine (CSL HA Antigen) 2010 (Biological); Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011 (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: Crucell Holland BV

Official(s) and/or principal investigator(s):
Michael Seiberling, MD, Principal Investigator, Affiliation: Covance Clinical Research Unit AG


The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune and CSL), in groups of young and elderly adults, using the EMA (European Medicines Agency) regulation as a guideline.

Clinical Details

Official title: Randomized, Parallel-group, Double-blind Multi-center Phase III Study to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers, in Elderly and Young Adults

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome:

Immunogenicity - Geometric Mean Titer Fold Increase From Baseline

Immunogenicity - Seroprotection Rate

Immunogenicity - Seroconversion Rate

Secondary outcome: Number of Participants With Local and Systemic Adverse Events

Detailed description: The objectives of this study are to evaluate the humoral immunogenicity and safety of the parenteral formulation of the 2010/2011-season influenza vaccine, Inflexal V, using HA antigen obtained from 2 different production facilities, and to compare the immunogenicity of both formulations to pre-defined EMA criteria for the annual relicensing of seasonal influenza vaccines. The evaluation will be done in young adults and elderly.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Healthy female and male adults

- Aged ≥18 years on Day 1

- Written informed consent

Exclusion Criteria:

- Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or

other acute disease

- Acute febrile illness (≥38. 0 °C)

- Prior vaccination with an influenza vaccine (including the H1N1 pandemic swine flu

vaccine) in the past 330 days

- Known hypersensitivity to any vaccine component

- Previous history of a serious adverse reaction to influenza vaccine

- History of egg protein allergy or severe atopy

- Known blood coagulation disorder

- Chronic (longer than 14 days) administration of immunosuppressants or other

immune-modifying drugs within 6 months before the first dose of the study vaccine, incl. oral corticosteroids in dosages of ≥0. 5 mg/kg/d prednisolone or equivalent (inhaled or topical steroids are allowed)

- Known immunodeficiency (incl. leukemia, cancer, HIV seropositivity)

- Investigational medicinal product received in the past 3 months (90 days)

- Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months

(90 days)

- Pregnancy or lactation

- Participation in another clinical trial

- Employee at the investigational site, or spouse and children of the investigator, or

relative living in the same household as the investigator and/or are dependent on the investigator

- Suspected non-compliance

Locations and Contacts

Covance Clinical Research Unit AG, Allschwil 4123, Switzerland

Cross Research S.A. Phase I Unit, Arzo 6864, Switzerland

Additional Information

Starting date: October 2010
Last updated: August 29, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017